Studies of IL-34 production by tumor cells in other cancer types indicates that aberrant expression of this growth factor cytokine can directly drive immune suppressive myeloid cells in their role in tumor resistance to T-cell directed checkpoint therapies. The gene discussed is IL34; the disease is cancer.